Bank of America has shifted its stance on Regeneron, raising the stock two notches to Buy from Underperform and lifting its price objective to $860 in a note on Wednesday.

The going has been strong for Regeneron Pharmaceuticals REGN over the past six months. Shares of this biotech giant have ...

When Regeneron snagged an FDA nod for eye drug Eylea in diabetic retinopathy in 2019, the agency opted against approving a 16-week dosing schedule despite positive data from a pivotal trial. Now, the ...

Here's why Regeneron (REGN) and Bayer's (BAYRY) fast growing Eylea for AMD is on target to eclipse $2 billion in global sales this year. Few drugs become multi-billion blockbusters, but those that do ...

TARRYTOWN, N.Y., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first presentation of positive two-year (96 weeks) results from the pivotal PULSAR ...

Biosimilars are coming for Regeneron and Bayer’s Eylea’s crown, but the blockbuster reign is under no immediate threat of being overthrown. That’s according to a new joint analysis from analysts with ...

The U.S. Food and Drug Administration has accepted for Priority Review Regeneron Pharmaceuticals, Inc.’s (NASDAQ:REGN) supplemental Biologics License Application (sBLA) for Eylea HD (aflibercept) ...

Another attempt to take on Regeneron and Bayer's juggernaut Eylea is struggling in the clinic. This time, it’s Ribomic’s wet age-related macular degeneration (AMD) therapy RBM-007. The small biotech ...

Credit: Regeneron. Eylea HD is supplied as a sterile, aqueous solution for intravitreal injection in a single-dose vial containing 8mg of aflibercept. The Food and Drug Administration (FDA) has ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced positive three-year (156-week) results for EYLEA HD (aflibercept) Injection 8 mg in patients with wet age-related macular degeneration or ...